<p>RxSight (NASDAQ:RXST - 获得免费报告) 于周一发布了其财报。公司报告称，该季度每股收益为（-0.16）美元，低于分析师预期的（-0.07）美元，Briefing.com 报道。该季度公司营收为 3,489 万美元，而分析师预期为 3,233 万美元。RxSight 的净资产收益率为-27.68%，净利润率为-44.01%。公司营收同比增长了 67.6%。在去年同期，公司每股收益为（-0.40）美元。</p>
<h2>RxSight 股价上涨 16.5%</h2>
<p>周二，纳斯达克 RXST 股价上涨 6.72 美元，达到 47.50 美元。公司股票交易量为 668,371 股，高于平均交易量 485,248 股。RxSight 的 52 周最低价为 20.66 美元，52 周最高价为 66.54 美元。公司市值为 17.6 亿美元，市盈率为-39.68，贝塔系数为 1.19。公司的 50 天移动平均价格为 53.44 美元，200 天移动平均价格为 53.43 美元。</p>
<h2>分析师评级变动</h2>
<p>近期有多位分析师对该公司发表了看法。Needham &amp; Company LLC 将 RxSight 的目标股价从 75.00 美元降至 54.00 美元，并在周二的研究报告中为该公司设定了 “买入” 评级。BTIG Research 将 RxSight 的价格目标从 72.00 美元上调至 73.00 美元，并在 7 月 15 日星期一的研究报告中为该公司设定了 “买入” 评级。Oppenheimer 将 RxSight 的目标股价从 72.00 美元降至 65.00 美元，并在周二的研究报告中为该股设定了 “表现优异” 评级。Stifel Nicolaus 将 RxSight 的目标股价从 70.00 美元降至 65.00 美元，并在周二的研究报告中为该公司设定了 “买入” 评级。最后，富国银行将 RxSight 的目标股价从 68.00 美元降至 54.00 美元，并在周二的研究报告中为该股设定了 “超重” 评级。根据 MarketBeat 的数据，共有七位分析师对该股票给予买入评级，目前市场普遍看好该公司，预期目标股价为 58.43 美元。</p>
<p><strong>阅读我们关于 RXST 的最新股票报告</strong></p>
<h2>内部人士的交易</h2>
<p>在其他 RxSight 新闻中，董事朱莉·安德鲁斯于 6 月 14 日星期五以每股 58.00 美元的均价出售了 15,625 股股票。交易总额为 906,250.00 美元。交易完成后，该董事在公司中直接持有 30,287 股股票，价值 1,756,646 美元。该交易已在证券交易委员会的一份文件中披露，可通过此超链接访问。此外，RxSight 的另一条消息显示，首席财务官雪莉·B·图南于 7 月 1 日星期一以每股 58.61 美元的均价出售了 10,000 股 RxSight 股票。交易总额为 586,100.00 美元。交易完成后，首席财务官现在持有公司 13,938 股股票，价值约 816,906.18 美元。有关此交易的披露可在此处找到。公司内部人士持有公司股份的比例为 9.36%。</p>
<h2>关于 RxSight（获得免费报告）</h2>
<p>RxSight, Inc.是一家商业化阶段的医疗器械公司，从事研究、开发、制造和销售用于白内障手术的可调光人工晶状体（LAL）在美国和国际市场的使用。公司提供的 RxSight 系统使医生能够为白内障手术后的患者定制和增强视力。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票胜过 RxSight</li>
<li>什么是股息成就者？简介</li>
<li>Uber 的盈利超预期：共享乘车和外卖激增</li>
<li>纽约证券交易所股票为投资者提供多样的优质选择</li>
<li>Hims &amp; Hers 报告季度业绩强劲：股价即将上涨</li>
<li>解析科技股：了解科技股的相关知识</li>
<li>Cloudflare 股价因业绩超预期和业绩指引上调而飙升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA"/></p>
<p><em>此即时新闻警报由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 时间不多了-6 月 25 日截止日期即将到来！（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEz"/></p>
<h2>现在是否值得投资 1,000 美元购买 RxSight？</h2>
<p>在考虑 RxSight 之前，您需要听到这个。</p>
<p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了顶级分析师悄悄告诉客户在更广泛市场注意之前购买的五只股票...而 RxSight 并不在名单上。</p>
<p>尽管 RxSight 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RXST

<p>RxSight（NASDAQ:RXST）报告的季度每股收益为（$0.16），低于预期（$0.09）。该公司营收为 3.489 亿美元，超过分析师的预期。RxSight 的营收同比增长了 67.6%。周二，该股上涨了 16.5%。多位分析师对该股票给予 “买入” 评级。内部人士一直在抛售该公司的股票。RxSight 是一家专门从事可调节光学人工晶状体的医疗器械公司</p>

<p>RxSight (NASDAQ:RXST - Get Free Report) released its earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09), Briefing.com reports. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The firm's revenue was up 67.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) EPS.</p>
<div class="lb-trans"><p>RxSight (NASDAQ:RXST - 获得免费报告) 于周一发布了其财报。公司报告称，该季度每股收益为（-0.16）美元，低于分析师预期的（-0.07）美元，Briefing.com 报道。该季度公司营收为 3,489 万美元，而分析师预期为 3,233 万美元。RxSight 的净资产收益率为-27.68%，净利润率为-44.01%。公司营收同比增长了 67.6%。在去年同期，公司每股收益为（-0.40）美元。</p>
</div><h2>RxSight Trading Up 16.5 %</h2>
<div class="lb-trans"><h2>RxSight 股价上涨 16.5%</h2>
</div><p>NASDAQ RXST traded up $6.72 on Tuesday, reaching $47.50. The company's stock had a trading volume of 668,371 shares, compared to its average volume of 485,248. RxSight has a 52 week low of $20.66 and a 52 week high of $66.54. The firm has a market cap of $1.76 billion, a PE ratio of -39.68 and a beta of 1.19. The business has a 50-day moving average price of $53.44 and a 200 day moving average price of $53.43.</p>
<div class="lb-trans"><p>周二，纳斯达克 RXST 股价上涨 6.72 美元，达到 47.50 美元。公司股票交易量为 668,371 股，高于平均交易量 485,248 股。RxSight 的 52 周最低价为 20.66 美元，52 周最高价为 66.54 美元。公司市值为 17.6 亿美元，市盈率为-39.68，贝塔系数为 1.19。公司的 50 天移动平均价格为 53.44 美元，200 天移动平均价格为 53.43 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts recently weighed in on the company. Needham &amp; Company LLC decreased their target price on RxSight from $75.00 to $54.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. BTIG Research increased their price objective on RxSight from $72.00 to $73.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, July 15th. Oppenheimer lowered their price objective on shares of RxSight from $72.00 to $65.00 and set an &#34;outperform&#34; rating on the stock in a research note on Tuesday. Stifel Nicolaus cut their target price on shares of RxSight from $70.00 to $65.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. Finally, Wells Fargo &amp; Company decreased their price target on shares of RxSight from $68.00 to $54.00 and set an &#34;overweight&#34; rating on the stock in a research report on Tuesday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $58.43.</p>
<div class="lb-trans"><p>近期有多位分析师对该公司发表了看法。Needham &amp; Company LLC 将 RxSight 的目标股价从 75.00 美元降至 54.00 美元，并在周二的研究报告中为该公司设定了 “买入” 评级。BTIG Research 将 RxSight 的价格目标从 72.00 美元上调至 73.00 美元，并在 7 月 15 日星期一的研究报告中为该公司设定了 “买入” 评级。Oppenheimer 将 RxSight 的目标股价从 72.00 美元降至 65.00 美元，并在周二的研究报告中为该股设定了 “表现优异” 评级。Stifel Nicolaus 将 RxSight 的目标股价从 70.00 美元降至 65.00 美元，并在周二的研究报告中为该公司设定了 “买入” 评级。最后，富国银行将 RxSight 的目标股价从 68.00 美元降至 54.00 美元，并在周二的研究报告中为该股设定了 “超重” 评级。根据 MarketBeat 的数据，共有七位分析师对该股票给予买入评级，目前市场普遍看好该公司，预期目标股价为 58.43 美元。</p>
</div><p><strong>Read Our Latest Stock Report on RXST</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RXST 的最新股票报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士的交易</h2>
</div><p>In other RxSight news, Director Julie Andrews sold 15,625 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $58.00, for a total transaction of $906,250.00. Following the completion of the transaction, the director now directly owns 30,287 shares in the company, valued at $1,756,646. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. In other RxSight news, Director Julie Andrews sold 15,625 shares of the company's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $58.00, for a total transaction of $906,250.00. Following the sale, the director now directly owns 30,287 shares of the company's stock, valued at $1,756,646. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link. Also, CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares of the company's stock, valued at approximately $816,906.18. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company's stock.</p>
<div class="lb-trans"><p>在其他 RxSight 新闻中，董事朱莉·安德鲁斯于 6 月 14 日星期五以每股 58.00 美元的均价出售了 15,625 股股票。交易总额为 906,250.00 美元。交易完成后，该董事在公司中直接持有 30,287 股股票，价值 1,756,646 美元。该交易已在证券交易委员会的一份文件中披露，可通过此超链接访问。此外，RxSight 的另一条消息显示，首席财务官雪莉·B·图南于 7 月 1 日星期一以每股 58.61 美元的均价出售了 10,000 股 RxSight 股票。交易总额为 586,100.00 美元。交易完成后，首席财务官现在持有公司 13,938 股股票，价值约 816,906.18 美元。有关此交易的披露可在此处找到。公司内部人士持有公司股份的比例为 9.36%。</p>
</div><h2>About RxSight (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 RxSight（获得免费报告）</h2>
</div><p>RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.</p>
<div class="lb-trans"><p>RxSight, Inc.是一家商业化阶段的医疗器械公司，从事研究、开发、制造和销售用于白内障手术的可调光人工晶状体（LAL）在美国和国际市场的使用。公司提供的 RxSight 系统使医生能够为白内障手术后的患者定制和增强视力。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than RxSight</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Uber's Earnings Beat: Rideshare and Delivery Surge</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Hims &amp; Hers Reports Stellar Quarter: Stock Set for a Rally</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票胜过 RxSight</li>
<li>什么是股息成就者？简介</li>
<li>Uber 的盈利超预期：共享乘车和外卖激增</li>
<li>纽约证券交易所股票为投资者提供多样的优质选择</li>
<li>Hims &amp; Hers 报告季度业绩强劲：股价即将上涨</li>
<li>解析科技股：了解科技股的相关知识</li>
<li>Cloudflare 股价因业绩超预期和业绩指引上调而飙升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RXST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 时间不多了-6 月 25 日截止日期即将到来！（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9013&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in RxSight right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买 RxSight？</h2>
</div><p>Before you consider RxSight, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 RxSight 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了顶级分析师悄悄告诉客户在更广泛市场注意之前购买的五只股票...而 RxSight 并不在名单上。</p>
</div><p>While RxSight currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 RxSight 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

RxSight（纳斯达克代码：RXST）公布季度财报，每股收益比预期低 0.09 美元